These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 34801029)

  • 21. Effect of body mass index and cholesterol-rich apolipoprotein-B-containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors-based therapy: A retrospective analysis.
    Hu Z; Zheng Y; Zheng J; Wang Y; Liao J; Liu Z; Li J; Cui H
    Cancer Med; 2024 Jun; 13(11):e7241. PubMed ID: 38819098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
    Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
    Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
    Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
    Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
    Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
    Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
    [No Abstract]   [Full Text] [Related]  

  • 25. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study.
    Ma C; Wang X; Guo J; Liu P
    Lipids Health Dis; 2021 Oct; 20(1):69. PubMed ID: 34598703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.
    Cai C; Shen Q; Shao J; Qu J; Zhou S; Zhou J
    Technol Cancer Res Treat; 2024; 23():15330338241279111. PubMed ID: 39175430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
    Yang X; Xiang M; Geng L; Wen Y; Du X
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study.
    Fan B; Tan X; Lou Y; Zheng Y; Zhang L; Wu X
    J Int Med Res; 2021 Oct; 49(10):3000605211046173. PubMed ID: 34758674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of microvascular density for response to anlotinib in advanced NSCLC.
    Liu D; Ding G
    Medicine (Baltimore); 2022 Jan; 101(3):e28647. PubMed ID: 35060554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    Ying J; Zhou D; Gu T; Huang J; Liu H
    BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials.
    Liu Y; Miao L; Chen X; Zhu X; Li Y; He J; Chen P; Dai S; Liu Z; Ma K; Wang N; Zhao Y; Chen N; Song W; Bai R; Cui J; Shu Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38459. PubMed ID: 38968520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers.
    Li AJ; Elmore RG; Chen IY; Karlan BY
    Gynecol Oncol; 2010 Jan; 116(1):78-81. PubMed ID: 19822357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    Li J; Ma C; Yuan X; Wang X; Li N; Yu R; Liao H
    Curr Oncol; 2022 Aug; 29(9):6125-6136. PubMed ID: 36135050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
    Li L; Zhang H; Xie Y; Su N; Su S; Zhang X; Cen W
    Comput Math Methods Med; 2022; 2022():1475871. PubMed ID: 35251294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yao JJ; He XJ; Lawrence WR; Zhang WJ; Kou J; Zhang F; Zhou GQ; Wang SY; Sun Y
    Cell Physiol Biochem; 2018; 48(1):285-292. PubMed ID: 30011397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.